Pyxis Oncology Statistics
Total Valuation
Pyxis Oncology has a market cap or net worth of $69.11 million. The enterprise value is $11.93 million.
Important Dates
The last earnings date was Monday, November 3, 2025, before market open.
| Earnings Date | Nov 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Pyxis Oncology has 62.26 million shares outstanding. The number of shares has increased by 13.72% in one year.
| Current Share Class | 62.26M |
| Shares Outstanding | 62.26M |
| Shares Change (YoY) | +13.72% |
| Shares Change (QoQ) | +1.03% |
| Owned by Insiders (%) | 6.01% |
| Owned by Institutions (%) | 26.44% |
| Float | 41.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 24.29 |
| Forward PS | n/a |
| PB Ratio | 1.00 |
| P/TBV Ratio | 1.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.23 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.29, with a Debt / Equity ratio of 0.28.
| Current Ratio | 4.29 |
| Quick Ratio | 3.93 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -87.28% and return on invested capital (ROIC) is -39.41%.
| Return on Equity (ROE) | -87.28% |
| Return on Assets (ROA) | -34.33% |
| Return on Invested Capital (ROIC) | -39.41% |
| Return on Capital Employed (ROCE) | -95.84% |
| Revenue Per Employee | $64,091 |
| Profits Per Employee | -$2.21M |
| Employee Count | 44 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.88M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -30.62% in the last 52 weeks. The beta is 1.38, so Pyxis Oncology's price volatility has been higher than the market average.
| Beta (5Y) | 1.38 |
| 52-Week Price Change | -30.62% |
| 50-Day Moving Average | 3.79 |
| 200-Day Moving Average | 1.99 |
| Relative Strength Index (RSI) | 20.22 |
| Average Volume (20 Days) | 1,680,568 |
Short Selling Information
The latest short interest is 1.93 million, so 3.10% of the outstanding shares have been sold short.
| Short Interest | 1.93M |
| Short Previous Month | 4.52M |
| Short % of Shares Out | 3.10% |
| Short % of Float | 4.68% |
| Short Ratio (days to cover) | 3.09 |
Income Statement
In the last 12 months, Pyxis Oncology had revenue of $2.82 million and -$97.09 million in losses. Loss per share was -$1.57.
| Revenue | 2.82M |
| Gross Profit | 2.82M |
| Operating Income | -82.63M |
| Pretax Income | -98.97M |
| Net Income | -97.09M |
| EBITDA | -80.47M |
| EBIT | -82.63M |
| Loss Per Share | -$1.57 |
Full Income StatementBalance Sheet
The company has $76.26 million in cash and $19.07 million in debt, giving a net cash position of $57.18 million or $0.92 per share.
| Cash & Cash Equivalents | 76.26M |
| Total Debt | 19.07M |
| Net Cash | 57.18M |
| Net Cash Per Share | $0.92 |
| Equity (Book Value) | 68.78M |
| Book Value Per Share | 1.11 |
| Working Capital | 63.69M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$72.37 million and capital expenditures -$9,000, giving a free cash flow of -$72.37 million.
| Operating Cash Flow | -72.37M |
| Capital Expenditures | -9,000 |
| Free Cash Flow | -72.37M |
| FCF Per Share | -$1.16 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -2,930.25% |
| Pretax Margin | -3,509.47% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Pyxis Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.72% |
| Shareholder Yield | -13.72% |
| Earnings Yield | -140.47% |
| FCF Yield | -104.72% |
Analyst Forecast
The average price target for Pyxis Oncology is $6.75, which is 508.11% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.75 |
| Price Target Difference | 508.11% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 42.08% |
| EPS Growth Forecast (5Y) | -10.62% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pyxis Oncology has an Altman Z-Score of -5.79 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.79 |
| Piotroski F-Score | 2 |
